Pathway inhibition: emerging molecular targets for treating glioblastoma. - Wikidata - awgldk - TriplyDB

Pathway inhibition: emerging molecular targets for treating glioblastoma.

Pathway inhibition: emerging molecular targets for treating glioblastoma.

http://www.wikidata.org/entity/Q35021359

about

Novel delivery strategies for glioblastoma Ephs and Ephrins in malignant gliomas Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma.Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Dose-dense temozolomide: is it still promising?Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma Cells.Src family kinases differentially influence glioma growth and motility Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge.ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.Unique biology of gliomas: challenges and opportunities.Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling.Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.Anti-cancer Therapies in High Grade Gliomas.Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.Signal transduction molecule patterns indicating potential glioblastoma therapy approaches.MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.Simultaneous targeting of Eph receptors in glioblastoma Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.Migfilin sensitizes cisplatin-induced apoptosis in human glioma cells in vitro.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Current and future directions for Phase II trials in high-grade glioma.A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG).The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development.Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?Circulating biomarkers for gliomas.

P2860

Q27006099-07103897-C152-44FA-9734-D665FD0F4A58 Q27015780-E37B68AB-897F-4434-A1B0-7702F05D31D6 Q27333552-CDEAFAD8-F064-476C-8B82-40C693056FC5 Q30588679-15E175FA-D167-4AF8-BA9B-77B99770F036 Q33578960-1C2C8126-2A48-44C5-80FB-0B7ADB1E0193 Q33619401-CB829A8F-5640-42DE-84FD-9BF45A716F1F Q33753468-D0E4650A-298B-4AAE-A2E5-F62D5D482604 Q34417525-6CB0D4E2-95D2-449C-AF16-894AA1D76169 Q34451033-37F193BE-11F1-4388-ACB6-2BA9D5614752 Q35171890-2BBD5F42-AAFA-4772-B79F-65C1D07098E7 Q35624037-C9064455-FCD9-47A7-ADF2-02B0211909F4 Q35676452-FDB24279-74A1-4659-96FB-DD1448C5E3AA Q35943654-4C664CED-CC74-4393-8164-684176FFF29E Q36088612-3270EB1D-A565-4D1D-8D3B-68B3B8F7C8D5 Q36218089-10E711E6-614E-49E8-89D5-8B4469D5BEE1 Q36224057-213B33D0-F65D-4B57-8E27-F4E086C740FF Q36319721-34E94516-C90C-47E3-A018-67E021499FB7 Q36482578-FE7926A7-972B-43BE-B256-5E70CCA3E0EE Q36544158-07DA265D-48E2-42F6-AAE8-E6F6A0EA4CA8 Q36560547-BEB683E9-4EFC-4565-A179-4666D107F400 Q36626214-D9A02052-A2A4-4E19-A12B-32A46E1C0B10 Q36654402-C32BDF64-CB3B-496A-8C5B-E0B3A688F688 Q37021563-B21E3008-0E6A-4AF4-9D4A-67F6DFF76381 Q37046847-03D00154-92A1-4BA9-88F6-25F98C8C1627 Q37157311-2A2F0FC7-94B7-46BA-94DA-C9596F9732DF Q37212017-01E9C095-B553-43F4-B443-4E09D3268DBE Q37290626-3B85AC51-CEF2-4A3C-982B-6A689A5ED3FE Q37331814-9A672D1A-92B0-4F2A-A223-9500D7A28AEA Q37360227-B7B2E723-E825-437C-8012-85E33F3F3BB0 Q37492137-01B8181F-169E-4405-B1E3-559ED1E1E942 Q37621027-17960389-8B5A-4512-8419-86E7E4D101A6 Q37644953-FEBEAFE4-7C1C-4CEF-AED6-0AC228ED4D0B Q37660428-A60DDB4C-B56D-46CE-94C0-194457B4B110 Q37728696-0DB14CA0-09F9-4001-97E7-C59B79B7D36F Q38021521-D16D808E-5DFA-49A3-BD71-0D7F170C458B Q38094808-7C1046BB-881D-4ADC-B962-13E20305EBC9 Q38161380-D6B808E2-565A-4491-A760-79178F450463 Q38441203-DD991956-8864-442B-9F05-85E36B0BD01A Q38534723-079C1492-8C0E-4E49-B20E-E7E55EB81D6E Q38586617-A5093A47-733F-4C1E-A77C-13F9938B8268

P2860

Pathway inhibition: emerging molecular targets for treating glioblastoma.

http://www.wikidata.org/entity/Q35021359

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@ast

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@en

type

label

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@ast

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@en

prefLabel

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@ast

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@en

P1433

Q35021359-C1B92080-A9AC-4B33-8E2C-C8CA14A66D9E

P1476

Q35021359-D1A64DC6-F2D0-4DFE-8272-B84B11F4501A

P2093

Q35021359-3DE3BA84-5D17-4C68-B85B-1CF7D30B3769

Q35021359-B4E8333E-BD6E-4702-B173-7B2D2A22D279

Q35021359-BC998F4C-1B75-468B-9B20-C6550EEF9126

Q35021359-FA8D2777-21F8-41D7-A064-1D2E90B66700

P2860

Q35021359-007E3BC2-D7D7-4DA9-B033-800859D34769

Q35021359-037CD320-A260-498A-9F17-D3C5577E6B91

Q35021359-0BD78D9D-8AED-4078-9178-0A85DC2ECAE0

Q35021359-0BE87A4E-3957-424A-8481-47EEAB2C8986

Q35021359-174A3F69-B360-47B5-A6B0-ECB3D4FC289C

Q35021359-1C2241A1-A5B9-49BE-9466-3F0EB3850214

Q35021359-1D1FB306-6424-4007-B864-0518EF149CFA

Q35021359-1EA5A62A-E8D6-4492-8C0E-62A4DE2D9EDA

Q35021359-2111E641-40DB-4EA4-84C6-3150B095D01E

Q35021359-21C94433-18E2-41F3-95B5-95AFC66BB1A7

P304

Q35021359-36BCFAF7-B398-4715-ADEF-F0E66CF5C697

P31

Q35021359-9BB97F68-DB6D-4ADC-A48A-3AA35CF27B11

P356

Q35021359-30D5630C-8652-418D-B5B4-5EAD1BCF1D6A

P433

Q35021359-C54DE589-9BF1-4EA2-ADDE-11C03A1CFD25

P478

Q35021359-80F24B72-1613-41FC-90EE-F26F8DB17369

P50

Q35021359-50640D19-7844-4698-B490-C9FFC3C59F33

Q35021359-FBC82A3B-E289-4B1B-9D17-284057CCA5C0

P577

Q35021359-452FEC18-1787-436B-ACDC-4E50B283B501

P5875

Q35021359-1C1033BE-44E2-4ED4-83F3-A6E19E7250FF

P698

Q35021359-6A82D08F-3FF7-45A1-89BF-A95056D89FE8

P932

Q35021359-C0F0D6A9-5F48-42D2-AD38-86710C39BCC0

P356

P1433

P1476

Pathway inhibition: emerging molecular targets for treating glioblastoma.

@en

P2093

Alfred W K Yung

http://www.w3.org/2001/XMLSchema#string

Markus Weiler

http://www.w3.org/2001/XMLSchema#string

Michael Platten

http://www.w3.org/2001/XMLSchema#string

Tracy Batchelor

http://www.w3.org/2001/XMLSchema#string

P2860

Yes and PI3K bind CD95 to signal invasion of glioblastoma

Integrin-regulated FAK-Src signaling in normal and cancer cells

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

An integrated genomic analysis of human glioblastoma multiforme

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Tumor angiogenesis: therapeutic implications

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Integrins in cancer: biological implications and therapeutic opportunities

P304

566-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOR039

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51187147

http://www.w3.org/2001/XMLSchema#string

P698

21636705

http://www.w3.org/2001/XMLSchema#string

P932

3107100

http://www.w3.org/2001/XMLSchema#string